Share This Page
Drugs in ATC Class S01LA
✉ Email this page to a colleague
Drugs in ATC Class: S01LA - Antineovascularisation agents
| Tradename | Generic Name |
|---|---|
| VISUDYNE | verteporfin |
| MACUGEN | pegaptanib sodium |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class S01LA – Antineovascularisation Agents
What Are Antineovascularisation Agents and Their Therapeutic Role?
Antineovascularisation agents in ATC Class S01LA inhibit angiogenesis, targeting abnormal blood vessel growth in ocular diseases. Conditions include age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion.
Market Size and Growth Drivers
The global ophthalmic drugs market, valued at over USD 40 billion in 2022, exhibits compound annual growth rate (CAGR) of 4-6% through 2027.[1] The segment for anti-VEGF (vascular endothelial growth factor) therapies, key in S01LA, accounts for more than half of this value.
Main drivers:
- Rising prevalence of AMD and diabetic retinopathy.
- Aging populations increasing ocular disease incidence.
- Advances in drug delivery systems reducing injection frequency.
- Patent expiries leading to biosimilar entry.
Key Therapeutic Agents and Current Market Participants
Approved Drugs
| Drug Name | Active Compound | Approval Year | Market Share (2022) | Notable Features |
|---|---|---|---|---|
| Lucentis (ranibizumab) | Ranibizumab | 2006 | 40% | Multiple indications |
| Eylea (aflibercept) | Aflibercept | 2011 | 35% | Extended dosing intervals |
| Beovu (brolucizumab) | Brolucizumab | 2018 | 10% | Smaller molecule, less frequent injections |
Biosimilars and Price Competition
Biosimilars of ranibizumab and aflibercept entered markets from 2021 onward, reducing treatment costs and expanding accessibility.
R&D Trends and Innovative Directions
Drug Innovation
- Long-acting formulations aiming to extend dosing intervals beyond 12 weeks.
- Combination therapies targeting multiple pathways.
- Novel delivery systems such as port delivery systems or gene therapy.
Pipeline Overview
| Compound/Technology | Developer | Stage | Expected Approval | Targeted Indications |
|---|---|---|---|---|
| Port delivery system (Genentech) | Genentech, Roche | Phase 3 | 2023-2024 | AMD, diabetic retinopathy |
| Gene therapy (RGX-314) | REGENXBIO | Phase 2 | 2024-2025 | Wet AMD, other retinopathies |
Key Players in R&D
- Genentech (Roche)
- Bayer
- Novartis
- Regeneron Pharmaceuticals
Patent Landscape Overview
Patent Filing Trends
Between 2010 and 2022, patent filings for S01LA agents increased annually, peaking at 30 filings in 2019.[2] Major filings focus on:
- Novel molecules and formulations.
- Sustained-release delivery systems.
- Methods of administration.
Key Patent Holders
| Company | Number of Patents (2022) | Focus Areas |
|---|---|---|
| Genentech | 50 | Ranibizumab formulations, delivery methods |
| Bayer | 40 | Aflibercept variants, combination therapies |
| Novartis | 35 | Biosimilar development, drug delivery innovations |
Patent Expiration and Patent Cliff Risks
Many core patents for initial anti-VEGF agents expire between 2023 and 2025, opening markets for biosimilars and generics.
Regulatory and Market Barriers
- High costs of development and approval.
- Necessity for invasive intravitreal injections, limiting patient compliance.
- Patent litigation and patent thickets hinder biosimilar entry.
Competitive Strategies
- Diversification into combination therapies.
- Development of longer-acting agents.
- Enhancing patient convenience through innovative delivery devices.
Key Takeaways
- Market growth driven by aging populations and increasing prevalence of ocular neovascular diseases.
- Dominance by existing anti-VEGF therapies, but biosimilar entry accelerates price competition.
- R&D focuses on extending treatment intervals, combining therapies, and improving delivery.
- Patent expirations from 2023 to 2025 will influence market dynamics significantly.
- Companies like Genentech, Bayer, and Novartis lead in patent filings and innovation.
FAQs
1. How will patent expirations affect market competition? Patent expirations will likely lead to increased biosimilar and generic entry, lowering prices and expanding access.
2. Are there alternatives to intravitreal injections? Research explores sustained-release devices, gene therapies, and less invasive delivery systems.
3. What are the main challenges in developing new agents? Challenges include drug delivery, invasive administration, and regulatory approval hurdles.
4. Which regions represent the largest markets? North America and Europe dominate due to aging populations and high healthcare expenditure.
5. What future innovations are most promising? Longer-acting agents, combination therapies, and gene editing technologies.
References
[1] MarketsandMarkets. (2022). Ophthalmic drugs market research report.
[2] PatentScope. (2023). Patent filings for ATC Class S01LA.
[3] WHO. (2022). Global prevalence of eye diseases and projections.
[4] FDA. (2022). Approved ophthalmic drugs and labeling details.
[5] EMA. (2021). Regulatory pathways for biosimilar anti-VEGF agents.
More… ↓
